Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade

[1]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[2]  K. Syrigos,et al.  Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality , 2021, npj Precision Oncology.

[3]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[4]  P. Ascierto,et al.  Evolving impact of long-term survival results on metastatic melanoma treatment , 2020, Journal for ImmunoTherapy of Cancer.

[5]  J. Wolchok,et al.  Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Keegan,et al.  Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis , 2020, Journal for ImmunoTherapy of Cancer.

[7]  David L Rimm,et al.  Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.

[8]  M. Atkins,et al.  Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. , 2019, Immunotherapy.

[9]  J. Madore,et al.  Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. , 2019, Cancer cell.

[10]  J. Lunceford,et al.  T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Wolchok,et al.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  G. Mann,et al.  Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma , 2019, Clinical Cancer Research.

[13]  Mary E. Piper,et al.  Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing factor , 2018, RNA.

[14]  D. Schadendorf,et al.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[15]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[16]  J. Yates,et al.  NRDE-2, the human homolog of fission yeast Nrl1, prevents DNA damage accumulation in human cells , 2018, RNA biology.

[17]  Steven M. Anderson,et al.  Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden , 2018, Journal of Immunotherapy for Cancer.

[18]  James R. Anderson,et al.  Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[20]  E. Felip,et al.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[22]  M. Atkins,et al.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy. , 2016, The Lancet. Oncology.

[23]  J. Lunceford,et al.  Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Ascierto,et al.  Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. , 2016, The Lancet. Oncology.

[25]  Greta M. Massetti,et al.  Vital Signs: Melanoma Incidence and Mortality Trends and Projections — United States, 1982–2030 , 2015, MMWR. Morbidity and mortality weekly report.

[26]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[27]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Maxim N. Artyomov,et al.  Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens , 2014, Nature.

[29]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[30]  Antoni Ribas,et al.  Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma , 2014, Clinical Cancer Research.

[31]  A. Fojo,et al.  Why RECIST works and why it should stay--counterpoint. , 2012, Cancer research.

[32]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[33]  A. F. Bochner,et al.  Small regulatory RNAs inhibit RNA Polymerase II during the elongation phase of transcription , 2010, Nature.

[34]  Max Kuhn,et al.  Building Predictive Models in R Using the caret Package , 2008 .

[35]  Thomas Lengauer,et al.  ROCR: visualizing classifier performance in R , 2005, Bioinform..

[36]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[37]  H Schipper,et al.  Shifting the cancer paradigm: must we kill to cure? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Brandon M. Greenwell,et al.  Variable Importance Plots - An Introduction to the vip Package , 2020, R J..

[39]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[40]  Mark Gardner,et al.  Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. , 2018, The Journal of molecular diagnostics : JMD.

[41]  J. Lunceford,et al.  IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .

[42]  T. Lumley,et al.  gplots: Various R Programming Tools for Plotting Data , 2015 .

[43]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.